Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone specific prior treatments.Efficac..
Enzalutamide is approved by the USFDA for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
The FDA has authorized enzalutamide for the treatment of non-metastatic castration-sensitive prostate cancer in cases of biochemical recurrence.The Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma US, I..
Capivasertib with fulvestrant is approved by the USFDA for breast cancer treatment
Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant was approved by the Food and Drug Administration on November 16, 2023, for adult patients with hormone receptor (HR)-positive, human epidermal gro..
Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma
The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the initial treatment of adults with ..
Repotrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2023.This FDA approval is the f..
FDA revises pembrolizumab’s indication for gastric cancer
The Food and Drug Administration updated the approved use of pembrolizumab (Keytruda, Merck) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for treating HER2-positive gastric or gastroeso..
Pembrolizumab with chemotherapy is approved by the USFDA for biliary tract cancer
On October 31, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin to treat biliary tract carcinoma (BTC) that has spread or is locally advanced but can not be..
Toripalimab-tpzi is approved by the FDA for nasopharyngeal carcinoma
In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people with locally advanced nasopharyngeal cancer (NPC) that has spread or co..
Mesenchymal stem cells (MSC) and platelet-rich plasma (PRP) therapy in the treatment of knee osteoarthritis
Feb 2024: Mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) therapy have shown potential in treating knee osteoarthritis (KOA) in China. A meta-analysis of randomized controlled studies looked into the effectiveness an..
The Life-Changing Treatment for Blood Cancer Finally Exposed!
Blood cancer is a type of cancer that affects both the blood and bone marrow. It is the fifth most common type of cancer in the world, with around 1.24 million new cases diagnosed each year. Wondering is blood cancer curable? Fin..